Galectin Therapeutics Inc... (GALT)
Galectin Therapeutics Inc. (GALT) Stock Price, Analysis & Data
| Bid | 2.5 |
| Market Cap | 346.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.44M |
| Beta | 0.35 |
| EPS (ttm) | -0.41 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.05 |
| P/B (ttm) | -1.71 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 4.16 |
| Volume | 388,200 |
| Avg. Volume (20D) | 662,019 |
| Open | 3.50 |
| Previous Close | 3.53 |
| Day's Range | 3.20 - 3.55 |
| 52-Week Range | 2.03 - 7.13 |
| Analyst | n/a |
| Price Target | 11 (219.77%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture ...
Financial Performance
In 2025, Galectin Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -30.84M, a decrease of -34.46%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for GALT stock is "null". The 12-month stock price forecast is 11, which is upside of 219.77% from the latest price.
Stock Forecasts
